This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

**Author(s):** Tahkola, Kyösti; Ahtiainen, Maarit; Kellokumpu, Ilmo; Mecklin, Jukka-Pekka; Laukkarinen Johanna; Laakkonen, Joni; Kenessey, Istvan; Jalkanen, Sirpa; Salmi, Marko; Böhm, Jan

**Title:** Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

**Year:** 2021

**Version:** Published version

**Copyright:** © 2020 the Author(s)

**Rights:** CC BY 4.0

**Rights url:** https://creativecommons.org/licenses/by/4.0/

**Please cite the original version:**

Tahkola, Kyösti, Ahtiainen, Maarit, Kellokumpu, Ilmo, Mecklin, Jukka-Pekka, Laukkarinen Johanna, Laakkonen, Joni, Kenessey, Istvan, Jalkanen, Sirpa, Salmi, Marko, Böhm, Jan. (2021). Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Archiv, 478(2), 209-217. https://doi.org/10.1007/s00428-020-02888-4
Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

Kyösti Tahkola 1,2 · Maarit Ahtiainen 3 · Ilmo Kellokumpu 1 · Jukka-Pekka Mecklin 1,4 · Johanna Laukkarinen 2,5 · Joni Laakkonen 6 · Istvan Kenessey 6 · Sirpa Jalkanen 6 · Marko Salmi 6 · Jan Böhm 7

Received: 27 February 2020 / Revised: 12 June 2020 / Accepted: 7 July 2020
© The Author(s) 2020

Abstract
Immune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invasion, and histopathological grade. CD73 positivity in tumour-infiltrating lymphocytes was significantly associated with lymph node metastasis. Lymphocytic CD73 positivity was also associated with staining positivity in both stroma and vascular structures. In addition, CD73 positivity in vascular structures and stroma were associated with each other. There were no significant associations between CD73 positive tumour cells and CD73 positivity in any other cell types. PD-L1 expression was associated with CD73 staining positivity in stroma (p = 0.007) and also with histopathological grade (p = 0.033) and T class (p = 0.016) of the primary tumour. CD73 positivity in tumour cells was significantly associated with poor disease-specific (p = 0.021) and overall survival (p = 0.016). In multivariate analysis, CD73 positivity in tumour cells was an independent negative prognostic factor together with histopathological grade, TNM stage, and low immune cell score. In conclusion, high CD73 expression in tumour cells is associated with poor survival in PDAC independently of the number of tumour-infiltrating lymphocytes or TNM stage.

Keywords Pancreatic cancer · Microenvironment · CD73 · PD-L1 · Prognosis

Introduction
Tumour microenvironment has been shown to impact on cancer progression [1–4]. Malignant tumours like pancreatic ductal adenocarcinoma (PDAC) are known to develop several mechanisms in order to suppress the host immune system [5, 6]. In line with others, our previous results have shown an association between the number of tumour-infiltrating lymphocytes (TILs) and survival in various cancer types ([7–9]).
PDAC is the seventh deadliest cancer worldwide [10]. Approximately 80% of patients have an unresectable tumour at the time of diagnosis due to advanced disease [11] and survival rates remain low even after attempted curative surgery [12]. Despite the promising results of immune-modulating agents in many other cancers, the results in PDAC have been disappointing.

CD73, also called ecto-5′-nucleotidase (NT5E), is one of the major nucleotide metabolizing enzymes having an essential role in sustaining immune homeostasis. It dephosphorylates adenosine monophosphate (AMP) to adenosine, which in turn activates specific G protein-coupled receptors (GPCR) and suppresses immune reaction. The apical distribution of CD73 in normal pancreatic duct epithelial cells has been shown to shift to a more diffuse distribution in PDAC [13]. This probably promotes cancer cell aggressiveness, angiogenesis and metastasis [14–16]. CD73 also has non-enzymatic functions in cells, and there is evidence suggesting that CD73 also promotes the proliferation and migration of cancer cells independently of its enzymatic activity [17].

There are reports of CD73 overexpression in various cancers [18–24] showing an association with poor survival [16, 25]. However, opposite associations have also been reported [26]. One reason may be that CD73 is expressed in a variety of cell types such as certain lymphocyte populations, lymphatic and blood endothelial cells, subsets of epithelial cells, fibroblasts and cancer cells (Fig. 1). Often cell-specific expression has not been taken into account in these prognostic analyses. The prognostic value of CD73 in PDAC is still limited [27].

PD-L1 (also called B7-H1 or CD274) is an immunosuppressive molecule. According to earlier studies, high-level PD-L1 expression seems to be associated with poor differentiation, neural invasion and poor survival in PDAC [28].

Little is known so far about the prognostic impact of CD73 in PDAC, and there are no studies concerning co-expression and a possible interrelationship between CD73 and PD-L1. Targeting CD73 could be a novel cancer treatment strategy; it is currently under intensive research and several clinical trials are ongoing (www.clinicaltrials.gov).

The aim of this study was to ascertain whether cell-specific CD73 acts as a prognostic factor in PDAC and to evaluate its relationship to other factors in microenvironment, such as PD-L1 and immune cell score (ICS). This study was designed and performed according to the reporting recommendations for prognostic studies on tumour markers [29].

**Material and methods**

From 2000 to 2016, a total of 110 patients with stage I-IV PDAC were operated on in the Central Hospital of Central Finland, Jyväskylä, Finland. The surgical procedures included 20 classic pancreaticoduodenectomies, 82 pylorus-preserving pancreatoduodenectomies, 4 total pancreatectomies, and 4 distal pancreatic resections. Data were retrieved from our prospectively maintained and continuously updated population-based database established in 2000, including detailed information on patient and tumour characteristics, surgical treatment and complications, oncological treatments and follow-up. Patients with tumour-node-metastasis (TNM) stage III-IV \((n = 7)\) were excluded from the survival analysis. Neoadjuvant chemotherapy was not given to any of the patients, whereas 95% of patients received adjuvant chemotherapy.

**Histopathological examination**

All histopathological tumour specimens were reviewed by an experienced gastrointestinal histopathologist (JB). Tumour staging was done according to the 7th edition of the UICC/AJCC TNM categories [30]. The grading was performed according to the WHO classification of tumours 2010 [31].

---

**Fig. 1** CD73 expression in normal pancreas. a Immunoperoxidase staining of normal pancreas for CD73 (brown). b Multicolour immunofluorescence staining of a consecutive section of normal pancreas for CD73 (blue), pan-cytokeratin (green) and alpha-smooth muscle actin (red). Bars, 50 \(\mu\)m
Tumour sampling and immunohistochemistry

Tissue microarray blocks were constructed from formalin-fixed paraffin-embedded primary PDAC patient tumour samples. Two tissue cores 0.6 mm in diameter were taken both from the core of the tumour and the invasive margin from representative tumour blocks. Sections of 2 μm thickness were used for immunohistochemical (IHC) analyses. Staining for CD73 was conducted with rabbit monoclonal anti-CD73 antibody (D7F9A, Cell Signalling) and ultraView Universal DAB detection kit (Roche) for Ventana. Staining for CD3 and CD8 was conducted with anti-CD3 (LN 10, 1:200; Novocastra) and anti-CD8 (SP16, 1:400; Thermo Scientific) antibodies, using a Lab Vision Autostainer 480 (ImmunoVision Technologies Inc.). Staining for PD-L1 was conducted with anti-PD-L1 (E1L3N, 1:100; Cell Signalling Technology) antibody, using a BOND-III stainer (Leica Biosystems). PD-L1 staining was carried out using whole tissue sections.

Signal visualization for all IHC was done by diaminobenzidine and sections were counterstained with haematoxylin. In order to validate our TMA method for CD73, we analyzed the expression of CD73 in tumour cells (TC) using whole-section samples from 16 corresponding cases. The correspondence between whole sections and TMA punches was 100%; when samples from 16 corresponding cases. The correspondence expression of CD73 in tumour cells (TC) using whole-section samples was used to calculate hazard ratios for OS and DSS. Only variables with \( p < 0.05 \) in univariate analysis were entered into the multivariate analysis despite the a priori determined confusion variables. The statistical analyses were performed with IBM SPSS statistics 24 for Windows (IBM Corporation, Armonk, NY, USA).

Results

Patient demographics

A total of 110 of PDAC patients were included in this study. The distribution of samples regarding different variables is shown in Table 1.

Associations between CD73 expression and other histopathological variables

We analyzed the associations between clinical and histopathological variables, cell-specific CD73 positivity and PD-L1 positivity in tumour cells (Tables 2 and 3).

High-level CD73 expression in tumour cells (CD73+TC) was positively associated with PD-L1 expression, perineural invasion and histopathological grade (Table 2). CD73
positivity in TILs was significantly associated with lymph node metastasis. Lymphocytic CD73 positivity was also associated with staining positivity in both stroma and vascular structures (Table 3). In addition, CD73 positivity in vascular structures and stroma was associated with each other. There were no associations between CD73+TC and CD73 positivity in any other cell types in the tumour area.

PD-L1 positivity in tumour cells was also associated with CD73 staining positivity in stroma and also with high histopathological grade and low T class of the primary tumour.

CD73 expression and survival

Regarding the whole study group, the median follow-up time was 44 (IQR 12.0 to 57.0) months for those alive at the end of follow-up. The estimated median overall survival (OS) for all patients was 23 [95% CI: (18.6–27.4)] months. CD73+TC was significantly associated with poor disease-specific survival (DSS) ($p = 0.021$) and OS ($p = 0.016$) (Fig. 3). In the multivariate analysis, CD73+TC was an independent negative prognostic factor together with histopathological grade, TNM stage and low ICS (Table 4).

High-level CD73 expression in tumour stroma, TILs or vascular structures did not show any significant correlation with survival (Table 3).

Discussion

Our results show that a high CD73 expression in tumour cells is associated with poor survival in PDAC independently of ICS or TNM stage. We moreover found an association between high expression of CD73+ in tumour cells and perineural invasion. PD-L1 expression and high CD73 expression in both tumour cells and in stroma were significantly associated with each other. Moreover, we demonstrated that patients with high CD73 expression in TILs were more likely to have lymph node metastasis.

Earlier studies have reported similar results concerning the impact of CD73 on PDAC survival [28]. In a mouse experiment published by Stagg et al., CD73 deficiency led to increased number of CD8+ T cells in tumours. This was thought to be one factor behind the protective effect of CD73 deficiency [32]. According to another mouse model, high CD73 expression in T-lymphocytes was associated with an “exhausted” phenotype of T cells [33]. According to the present study, it is possible that, in PDAC, CD73 suppresses immune response by impacting on TILs activity rather than their number.

To the best of our knowledge, these results show for the first time the association between high CD73 expression in tumour cells and perineural invasion indicating that CD73 overexpression may be implicated in this process.
According to the literature, perineural invasion can be found in some form in almost all surgically removed PDACs when searched with thin slice thickness and also taking account of perineural invasion with low severity. However, according to a meta-analysis of 3538 patients, the incidence of perineural invasion was 71.7%, which is in line with that found in our study population [34]. This discrepancy between the incidences found in routine histopathological analysis and in a meticulous search with thin slice thickness is thought to reflect the variable severity of perineural invasion. In other words, perineural invasion with low severity is sometimes not found in histopathological analysis when using routine slice thickness. The same meta-analysis, however, shows that perineural invasion found in routine histopathological analysis seems to be an independent prognostic factor for poor survival.

### Table 1 Clinicopathological characteristics

| n = 110 | n/median | %/min-max |
|---------|----------|-----------|
| Age, years | 67.0 | 45–82 |
| Gender | | |
| Male | 58 | 52.7 |
| Female | 52 | 47.3 |
| T-stage | | |
| pT1 | 3 | 2.7 |
| pT2 | 22 | 20.0 |
| pT3 | 81 | 73.6 |
| pT4 | 4 | 3.6 |
| N-stage | | |
| pN0 | 32 | 29.1 |
| pN1 | 78 | 70.9 |
| Stage | | |
| IA | 3 | 2.7 |
| IB | 7 | 6.4 |
| IIA | 20 | 18.2 |
| IIB | 73 | 66.4 |
| III | 3 | 2.7 |
| IV | 4 | 3.6 |
| Histological grade | | |
| 1 | 30 | 27.3 |
| 2 | 65 | 59.1 |
| 3 | 7 | 6.4 |
| Perineural invasion | | |
| Positive | 36 | 34.6 |
| Negative | 68 | 65.4 |
| PD-L1 in tumour cells\(a\) | | |
| Positive | 5 | 4.5 |
| Negative | 105 | 95.5 |
| CD73+ tumour cell score\(b\) | | |
| High | 37 | 33.6 |
| Low | 73 | 66.4 |
| CD73+ TILs\(c\) | | |
| Positive | 55 | 53.9 |
| Negative | 47 | 46.1 |
| CD73+ stroma\(d\) | | |
| Strong | 38 | 34.5 |
| Moderate | 37 | 33.6 |
| Weak | 35 | 31.8 |
| CD73+ vessels\(e\) | | |
| High | 68 | 61.8 |
| Low | 42 | 38.2 |

\(a\) Tumour samples were considered PD-L1 positive when >1% of the tumour cells were positive for PD-L1

\(b\) The score (0–300) was formed by multiplying the proportion of stained tumour cells by the staining intensity (0–3). 90 was set as a cut off value

\(c\) Tumour samples were considered positive when >3% of lymphocytes were positive for CD73

\(d\) Tumour stroma positivity was considered weak, moderate or strong when <5%, 5–16% or >17% of the stromal area was stained, respectively

\(e\) Due to the strong staining intensity of vascular structures, 95% was set as a cut off value for CD73 positivity of vascular structures

### Table 2 Clinicopathological variables and their association with CD73 expression in tumour cells (CD73+ TC)

| CD73 + TC high | CD73 + TC low | p value |
|----------------|----------------|---------|
| n = 37 | n = 73 |
| n | % | n | % |

| T-class | 0.985 | |
| 1 | 1 | 2.8 | 2 | 2.7 |
| 2 | 7 | 19.4 | 15 | 20.5 |
| 3 | 27 | 75.0 | 5 | 72.6 |
| 4 | 1 | 2.8 | 3 | 4.1 |

| N-class | 0.916 | |
| 0 | 11 | 29.7 | 21 | 28.8 |
| 1 | 26 | 70.3 | 52 | 71.2 |

| Grade | 0.013 | |
| 1 | 5 | 14.7 | 25 | 36.8 |
| 2 | 24 | 70.6 | 41 | 60.3 |
| 3 | 5 | 14.7 | 2 | 2.9 |

| Perineural invasion | 0.041 | |
| Negative | 7 | 20.6 | 29 | 40.8 |
| Positive | 27 | 79.4 | 42 | 59.2 |

| CD73+ vessels | 0.377 | |
| Negative | 12 | 32.4 | 30 | 41.1 |
| Positive | 25 | 67.6 | 43 | 58.9 |

| CD73+ TILs | 0.930 | |
| Negative | 15 | 45.5 | 32 | 46.4 |
| Positive | 18 | 54.5 | 37 | 53.6 |

| CD73+ Stroma | 0.328 | |
| Weak | 9 | 24.3 | 26 | 35.6 |
| Moderate | 12 | 32.4 | 25 | 34.2 |
| Strong | 16 | 43.2 | 22 | 30.1 |

| PD-L1 TC | 0.025 | |
| 0 | 33 | 89.2 | 72 | 98.6 |
| 1 | 4 | 10.8 | 1 | 1.4 |

| Immune cell score | 0.947 | |
| Low | 11 | 29.7 | 23 | 32.4 |
| Moderate | 13 | 35.1 | 23 | 32.4 |
| High | 13 | 35.1 | 25 | 35.2 |
In our study cohort, high CD73 expression in both tumour cells and in stroma was significantly associated with PD-L1 expression in tumour cells. Similar findings have been reported in gastrointestinal neuroendocrine neoplasms [35]. Deng et al. demonstrated a close connection between these two immunosuppressive molecules in their recent mouse experiment concerning head and neck cancer [33]. They showed that blockade of CD73 reversed the exhausted T cell phenotype through downregulation of PD-1 and CTLA-4 on T cells. Mice studies have also proven that blocking adenosine receptor A2 (A2AR) enhances the efficacy of anti-PD-1 antibodies through enhanced antitumour T cell responses [36, 37].

Although the evidence of the pro-tumoural effect of high CD73 expression is increasing, the impact of CD73 expression in TILs is far from clear. Immunosuppressive regulatory T cells (Treg) as well as T helper 17 cells and myeloid-derived suppressor cells are known to express CD73 [38–40]. We showed that PDAC patients with CD73+ TILs were more likely than the controls to develop lymph node metastases. We think this association may reflect the impact of immunosuppressive cells mentioned above. However, double staining of immune cells is needed in the future to confirm this hypothesis. Correspondingly, Ma et al. [41] showed that the increased expression of A2AR correlated with positive lymph node metastases.

Table 3 Interrelationship between clinicopathological variables and their association to 5-year DSS

| Variables       | T class | N class | Perineural invasion | Vessels CD73+a | LC CD73+b | Stroma CD73+b | TC CD73+b | PD-L1 TC+ | ICS* | 5-year DSSd |
|-----------------|---------|---------|---------------------|----------------|-----------|---------------|-----------|-----------|------|-------------|
| Grade           | NS      | NS      | NS                  | 0.073†         | NS        | 0.060†        | 0.013‡    | 0.010†    | NS   | 0.008↓     |
| T class         | 0.057†  | NS      | NS                  | NS             | NS        | 0.016↓        | 0.032↓    | NS        | NS   |             |
| N class         | NS      | NS      | NS                  | 0.001†         | NS        | NS            | NS        | NS        | NS   |             |
| Perineural invasion | NS      | NS      | NS                  | 0.041†         | NS        | NS            | NS        | NS        | NS   |             |
| Vessels CD73+   | 0.004†  | >0.001† | NS                  | NS             | NS        | 0.072↑        | 0.056↑    | NS        | NS   |             |
| LC CD73+a       | 0.023↑  |         | NS                  | NS             | NS        | 0.059↑        | 0.038↑    | NS        | NS   |             |
| Stroma CD73+    | 0.007↑  | 0.030↑  | NS                  | NS             | NS        | NS            | NS        | NS        | NS   |             |
| TC CD73+b       |         |         | 0.057     |                 | NS        | NS            | NS        | NS        | NS   |             |
| PD-L1 TC+       |         |         | 0.025↑    | NS             | NS        | NS            | NS        | NS        | NS   |             |
| ICS*            |         |         |         |                 |           |               |           |           | 0.014↑ |             |

Nonsignificant (NS), p > 0.1; bold value, p < 0.05. Chi-square test. Arrows show the direction of association

a CD73+ Lymphocytes (low/high)

b CD73+ Tumour cells (low/high)

c Immune cell score

d Log rank test used

In our study cohort, high CD73 expression in both tumour cells and in stroma was significantly associated with PD-L1 expression in tumour cells. Similar findings have been reported in gastrointestinal neuroendocrine neoplasms [35]. Deng et al. demonstrated a close connection between these two immunosuppressive molecules in their recent mouse experiment concerning head and neck cancer [33]. They showed that blockade of CD73 reversed the exhausted T cell phenotype through downregulation of PD-1 and CTLA-4 on T cells. Mice studies have also proven that blocking adenosine receptor A2 (A2AR) enhances the efficacy of anti-PD-1 antibodies through enhanced antitumour T cell responses [36, 37].

Fig. 3 Prognostic impact of CD73+TC on DSS (a) and OS (b)

\[ Springer \]
node status in head and neck squamous cell carcinoma. This refers to the significance of the immunosuppressive adenosine pathway in cancer progression. Our study has some limitations. Sampling error is a well-known risk related to the use of TMA. To minimize this risk, we analyzed whole sections of 16 cases to validate our method, and the correspondence between TMA and whole sections was excellent. The use of consecutive patient series from a single geographical area to avoid a selection bias strengthens our study. In addition, double assessing of IHC staining by two independent researchers increases the reliability of the results.

The development of the combined treatments of anti-CD73 with other immune-modulating agents such as anti-PD1 will potentially bring new hope for patients with PDAC. In the future, personalized cancer therapy will lead to an increasing need for applicable biomarkers. There also remains a need for basic research on our fine-tuned immune system.

In conclusion, our study shows that high expression of CD73 is an independent prognostic factor in PDAC associated with perineural invasion. We furthermore demonstrate an association between CD73 and PD-L1 expression in pancreatic tumour cells. In addition, our study shows for the first time that patients with high CD73 expression in TILs are more likely to have lymph node metastasis.

Acknowledgements We thank Heini Huhtala for her excellent assistance in statistical analysis.

Contributions All authors met the criteria listed in the ICMJE recommendations for the qualification of authorship.

Authors' contributions Drs. Tahkola and Böhm had full access to all the data and take responsibility for the integrity of the data and the accuracy of the analysis.

Table 4 Uni- and multivariate analysis with Cox proportional hazard model

|                | Uni- | Multivariate analysis |        |        |
|----------------|------|-----------------------|--------|--------|
|                | HR (95% CI) | HR (95% CI) |       |        |
| CD73 (TC)      |       |                       |        |        |
| Negative       | 0.019 | 0.025                 | 0.035  | 0.043  |
| Positive       | 1.79  | 1.81                  | 1.83   | 3.29   |
| Tumour grade   |       |                       |        |        |
| 1              | 0.006 | 0.012                 | 0.006  | 0.11   |
| 2              | 1.96  | 1.96                  | 2.00   | 3.54   |
| 3              | 3.70  | 5.25                  | 5.10   | 17.61  |
| TNM Stage      |       |                       |        |        |
| IA             | 1.13  | 1.18                  | 0.041  | 0.027  |
| IB             | 0.54  | 0.33                  | 0.36   | 1.22   |
| IIA            | 0.56  | 0.48                  | 0.40   | 0.84   |
| IIB            | 1     | 1                     | 1      |        |
| ICS*           |       |                       |        |        |
| High           | 0.019 | 0.018                 | 0.004  | 0.003  |
| Moderate       | 1.82  | 2.19                  | 2.47   | 4.82   |
| Low            | 2.25  | 2.82                  | 3.07   | 5.95   |

*a Immune cell score

Concept and design: Tahkola, Mecklin, Jalkanen and Böhm. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Tahkola, Salmi and Böhm. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Tahkola and Böhm. Administrative, technical, or material support: Ahtiainen, Kellokumpu, Mecklin, Laukkarinen, Laakkonen, Kenessey, Jalkanen, Salmi and Böhm. Supervision: Mecklin, Laukkarinen, Kellokumpu and Böhm.

Funding information This study received funding from the Finnish Cancer Foundation, the Jane and Aatos Erkko Foundation and the State Research Funding.

Compliance with ethical standards

The use of patient samples and the data inquiry were approved by the Oulu University Hospital Ethics Committee. The need to obtain written or oral consent from patients to use their samples in research was waived by the Finnish National Authority for Medicolegal Affairs (VALVIRA, Dnr 10832/06.01.03.01/2014).

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Clark AG, Vignjevic DM (2015) Modes of cancer cell invasion and the role of the microenvironment. Onco-Gen Cell Biol 36:13–22. https://doi.org/10.1016/j.cjb.2015.06.004

2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

3. Fouad YA, Aanen C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016–1036

4. Cheu V, Toh HC, Abastado J-P (2012) Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012:608406–608410. https://doi.org/10.1155/2012/608406

5. Fridman WH, Mlécnik B, Bin dea G et al (2011) Immunosurveillance in human non-viral cancers. Curr Opin Immunol 23:272–278. https://doi.org/10.1016/j.coi.2010.12.011

6. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322

7. Takhkola K, Mecklin J-P, Wirta E-V, Ahtiainen M, Helminen O, Böhm J, Kellokumpu I (2018) High immune cell score predicts improved survival in pancreatic cancer. Virchows Arch. 472. https://doi.org/10.1007/s00428-018-2297-1

8. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev 12:298–306. https://doi.org/10.1038/nrc3245

9. Wirta EV, Seppala T, Friman M et al (2017) Immunoscore in mismatch repair-proficient and -deficient colon cancer. J Pathol Res 3:203–213. https://doi.org/10.1002/cpr.71

10. Fitzmaurice C, Akinyemiju TF, Al Lami FH et al (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 4:1553–1568. https://doi.org/10.1001/jamaoncology.2018.2706

11. Li D, Xie K, Wolff R, Abbuzzese JL (2004) Pancreatic cancer. Lancet (London, England) 363:1049–1057. https://doi.org/10.1016/S0140-6736(04)15841-8

12. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urban S, Zeh JH, Katz MHG (2016) Potentially curable pancreatic cancer: A meta-analysis and systematic review. Oncotarget 8:57327–57336. https://doi.org/10.18632/oncotarget.16905

13. Sadej R, Spychala J, Skladanowski AC (2006) Expression of ecto-5′-nucleotidase in normal thyroid carcinomas. Histopathology 48:612–614

14. Sargut M, Goess R, Friess H, Ceyhan GO (2017) The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - a systematic review and meta-analysis. Surg Oncol 26:105–115. https://doi.org/10.1016/j.suronc.2017.01.007

15. Zhou X, Zhi X, Zhou P et al (2007) Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 17:1341–1346

16. Koivisto MK, Tervahartiala M, Kenessy I, Jalkanen S, Boström PJ, Salini M (2019) Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 40:84–92. https://doi.org/10.1038/carcin/bgy154

17. Zhou L, Jia S, Chen Y, Wang W, Wu Z, Yu W, Zhang M, Ding G, Cao L (2019) The distinct role of CD73 in the progression of pancreatic cancer. J Mol Med (Berl) 97:803–815. https://doi.org/10.1007/s00109-018-1472-0

18. Zhuan-Sun Y, Huang F, Feng M, Zhao X, Chen W, Zhu Z, Zhang S (2017) Prognostic value of CD73 adenosinergic pathway in solid tumor: a meta-analysis and systematic review. Oncotarget 8:57327–57336. https://doi.org/10.18632/oncotarget.23056
35. Ono K, Shiozawa E, Ohike N, Fujii T, Shibata H, Kitajima T, Fujimasa K, Okamoto N, Kawaguchi Y, Nagumo T, Tazawa S, Homma M, Yamochi-Onizuka T, Norose T, Yoshida H, Murakami M, Tate G, Takimoto M (2018) Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: a retrospective study of 136 patients. Oncol Lett 15: 2123–2130. https://doi.org/10.3892/ol.2017.7569

36. Allard B, Pommey S, Smyth MJ, Stagg J (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626–5635. https://doi.org/10.1158/1078-0432.CCR-13-0545

37. Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK (2015) Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3:506–517. https://doi.org/10.1158/2326-6066.CIR-14-0211

38. Mandapathil M, Hildorfer B, Szczepanski MJ, Czstowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176–7186. https://doi.org/10.1074/jbc.M109.047423

39. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rébé C, Ghiringhelli F (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36:362–373. https://doi.org/10.1016/j.immuni.2011.12.019

40. Chen S, Fan J, Zhang M, Qin L, Domínguez D, Long A, Wang G, Ma R, Li H, Zhang Y, Fang D, Sosman J, Zhang B (2019) CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat Commun 10: 150. https://doi.org/10.1038/s41467-018-08123-8

41. Ma S-R, Deng W-W, Liu J-F, Mao L, Yu G-T, Bu L-L, Kulkami AB, Zhang WF, Sun ZJ (2017) Blockade of adenosine A2A receptor enhances CD8(+) T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer 16:99. https://doi.org/10.1186/s12943-017-0665-0

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.